Memocit (Citicoline Sodium)

Citicoline is broken down into choline and cytidine, which are precursors for phosphatidylcholine synthesis. This supports neuronal membrane repair and increases acetylcholine levels, enhancing cholinergic neurotransmission. The compound also promotes mitochondrial function and neuroprotective pathways, helping to maintain cerebral metabolism.

The appropriate dose of Memocit is determined by the prescribing healthcare professional based on the individual’s clinical condition, age, renal and hepatic function, and response to therapy. Patients should follow the dosage instructions provided by their prescriber and not adjust the dose on their own.

Safety data for citicoline in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss individual circumstances and consider alternative therapies when appropriate.

To request Memocit, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with other nootropics, citicoline provides a direct source of choline and cytidine, supporting membrane synthesis and acetylcholine production. Unlike some stimulatory agents, it has a favorable safety profile and is often chosen for conditions where neuronal repair and vascular support are priorities, such as post‑stroke or vascular dementia.

Memocit should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Memocit is taken orally, usually with water. The tablet should be swallowed whole and not chewed or crushed unless otherwise directed by a healthcare professional. Administration can be with or without food, depending on the prescriber’s recommendation.

Serious but rare risks include significant hypotension, allergic reactions such as rash or urticaria, and elevations in hepatic enzymes. Patients should seek immediate medical attention if they experience symptoms like severe dizziness, swelling, breathing difficulties, or unexplained jaundice.

Memocit is contraindicated in individuals with known hypersensitivity to citicoline or any excipients in the tablet. Caution is advised for patients with uncontrolled hypertension, severe hepatic or renal impairment, and those taking monoamine oxidase inhibitors, unless a prescriber determines the benefits outweigh the risks.